August was the month of the comeback kids. Cramer reviews what drove the biggest winners

Stocks staged a broad August rebound, with Moderna (MRNA) up 156% and Palantir (PLTR) up 51.45% as investors increasingly credited improving fundamentals over bearish AI/disruption and slowing-growth narratives. The article highlights sharp rebounds in software (e.g., ServiceNow +33.05%) after fears of an “AI/SaaSpocalypse” proved overstated, alongside crypto strength (Coinbase +28.62%) as investors rotated toward hard assets amid concerns about U.S. government spending and rising debt costs. Overall, the comeback is framed as partly amplified by hedge-fund unwinds (Situational Awareness forced to unwind in late July), suggesting a near-term positive but partly flow-driven read-through for high-beta growth and crypto-linked exposures.

Analysis

The near-term tape suggests a squeeze regime more than a clean fundamentals regime: the biggest beneficiaries are the names where bearish positioning was most crowded and the operating story is easiest to re-anchor with one good print. That favors PLTR, CRM, NOW and VEEV in the next 1-3 months, but the follow-through depends on bookings, net retention, and AI monetization showing up in forward guidance rather than just sentiment repair.

The second-order effect is that AI fear is rotating, not disappearing. If enterprise software is proving sticky, the losers are likely point-solution vendors and research franchises whose pricing power gets tested only gradually; if that thesis is wrong, the reversal will show up first in slower upsell rates and longer sales cycles. On the hardware side, SMCI and SNDK are more cyclical than strategic: they can keep outrunning fundamentals as AI capex stays hot, but they are the fastest names to give back gains if hyperscaler spending normalizes.

The most interesting contrarian setup is that the market may be over-crediting a few headline catalysts while underpricing valuation reset risk elsewhere. MRNA looks like a classic event-driven overearn of good news until the melanoma program advances into cleaner probability-of-success data, while AEM vs NEM still looks like the cleaner way to express any further strength in gold without paying for operational noise. COIN remains a macro-beta proxy, but that trade only works if crypto stays the preferred hedge for weaker fiat confidence; a real rates rebound or BTC drawdown would reverse it quickly.

Key Decisions for Investors

• Add PLTR/CRM/NOW on pullbacks as a 1-3 month momentum-to-fundamentals basket; keep sizing moderate and cut if next-quarter billings or cRPO fail to confirm the re-rating.
• Pair long AEM / short NEM into any continued strength in gold; AEM is the cleaner operating leverage play, while NEM is more exposed to market skepticism about execution and capital allocation.
• Fade MRNA strength with a tactical short or call-sell strategy until the melanoma-vaccine program produces broader clinical validation; the move is vulnerable to a sharp giveback on any trial delay or safety signal.
• Treat SMCI and SNDK as momentum trades only, not core longs; enter on intraday or post-earnings weakness, but exit quickly if AI capex commentary from hyperscalers softens.
• Use COIN only as a high-beta crypto proxy, preferably via call spreads rather than outright stock, and abandon if BTC loses trend support or real yields reverse lower.